On Tuesday, Galectin Therapeutics Inc (NASDAQ:GALT) reported that its pipeline investigational drug GR-MD-02, designed to treat liver fibrosis, missed its primary endpoint in …
In a research report published today, MLV analyst Vernon Bernardino reiterated a Buy rating on shares of Galectin Therapeutics (NASDAQ:GALT) with a $16 price target, following final …
MLV’s healthcare analyst Vernon Bernardino today weighed in with his thoughts on several stocks, which have promising candidates in clinical development for liver diseaes, following the news …
